Clinical Trials
1
Active:0
Completed:0
Trial Phases
1 Phases
Not Applicable:1
Drug Approvals
1
EMA:1
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Not Applicable
1 (100.0%)Safety Study of a Single Dose of Pneumococcal Whole-Cell Vaccine in Healthy Adults
Not Applicable
Recruiting
- Conditions
- PREVENTION OF INVASIVE PNEUMOCOCCAL DISEASEPrevention of Pneumococcal-induced Acute Otitis Media
- Interventions
- Biological: Inactivated whole-cell Streptococcus pneumoniae vaccineDrug: Placebo
- First Posted Date
- 2025-07-10
- Last Posted Date
- 2025-07-31
- Lead Sponsor
- Serum Life Science Europe GmbH
- Target Recruit Count
- 30
- Registration Number
- NCT07059182
- Locations
- 🇺🇸
Rochester Clinical Research, Rochester, New York, United States
News
SIILTIBCY Receives Positive CHMP Opinion for Tuberculosis Detection in Europe
• The European Medicines Agency's CHMP has recommended SIILTIBCY, a novel tuberculosis skin test, for approval in Europe. • SIILTIBCY is designed to accurately detect TB, irrespective of prior BCG vaccination status, addressing a key diagnostic challenge. • Phase 3 clinical trials involving over 2,500 participants demonstrated the accuracy and safety of SIILTIBCY in diagnosing TB. • Upon European Commission approval, SIILTIBCY will be available in EU Member States, with SLS Europe managing authorization and BBio handling distribution.